{"pmid":32356307,"title":"From Hematologist's desk: The effect of COVID-19 on the blood system.","text":["From Hematologist's desk: The effect of COVID-19 on the blood system.","Am J Hematol","Sahu, Kamal Kant","Siddiqui, Ahmad Daniyal","32356307"],"journal":"Am J Hematol","authors":["Sahu, Kamal Kant","Siddiqui, Ahmad Daniyal"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32356307","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/ajh.25849","topics":["Mechanism","Diagnosis","Prevention"],"weight":1,"_version_":1666138495167496192,"score":9.490897,"similar":[{"pmid":32387301,"title":"The CoV-2 outbreak: how hematologists could help to fight Covid-19.","text":["The CoV-2 outbreak: how hematologists could help to fight Covid-19.","COVID-19 is a medical emergency, with 20 % of patients presenting with severe clinical manifestations. From the pathogenetic point of view, COVID-19 mimics two other well-known diseases characterized by cytokine storm and hyper-activation of the immune response, with consequent organ damage: acute graft-versus-host disease (aGVHD) and macrophage activation syndrome (MAS). Hematologists are confident with these situations requiring a prompt therapeutic approach for switching off the uncontrolled cytokine release; here, we discuss pros and cons of drugs that are already employed in hematology in the light of their possible application in COVID-19. The most promising drugs might be: Ruxolitinib, a JAK1/2 inhibitor, with a rapid and powerful anti-cytokine effect, tyrosine kinase inhibitors (TKIs), with their good anti-inflammatory properties, and perhaps the anti-Cd26 antibody Begelomab. We also present immunological data from gene expression experiments where TKIs resulted effective anti-inflammatory and pro-immune drugs. A possible combined treatment algorithm for COVID-19 is here proposed.","Pharmacol Res","Galimberti, Sara","Baldini, Chiara","Barate, Claudia","Ricci, Federica","Balducci, Serena","Grassi, Susanna","Ferro, Francesco","Buda, Gabriele","Benedetti, Edoardo","Fazzi, Rita","Baglietto, Laura","Lucenteforte, Ersilia","Di Paolo, Antonello","Petrini, Mario","32387301"],"abstract":["COVID-19 is a medical emergency, with 20 % of patients presenting with severe clinical manifestations. From the pathogenetic point of view, COVID-19 mimics two other well-known diseases characterized by cytokine storm and hyper-activation of the immune response, with consequent organ damage: acute graft-versus-host disease (aGVHD) and macrophage activation syndrome (MAS). Hematologists are confident with these situations requiring a prompt therapeutic approach for switching off the uncontrolled cytokine release; here, we discuss pros and cons of drugs that are already employed in hematology in the light of their possible application in COVID-19. The most promising drugs might be: Ruxolitinib, a JAK1/2 inhibitor, with a rapid and powerful anti-cytokine effect, tyrosine kinase inhibitors (TKIs), with their good anti-inflammatory properties, and perhaps the anti-Cd26 antibody Begelomab. We also present immunological data from gene expression experiments where TKIs resulted effective anti-inflammatory and pro-immune drugs. A possible combined treatment algorithm for COVID-19 is here proposed."],"journal":"Pharmacol Res","authors":["Galimberti, Sara","Baldini, Chiara","Barate, Claudia","Ricci, Federica","Balducci, Serena","Grassi, Susanna","Ferro, Francesco","Buda, Gabriele","Benedetti, Edoardo","Fazzi, Rita","Baglietto, Laura","Lucenteforte, Ersilia","Di Paolo, Antonello","Petrini, Mario"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387301","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.phrs.2020.104866","keywords":["baricitinib","begelomab","covid-19","gvhd","mas","ruxolitinib","tkis","tocilizumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666428892704931840,"score":66.96901},{"pmid":32323135,"title":"From the Editor's Desk: JGIM and COVID-19.","text":["From the Editor's Desk: JGIM and COVID-19.","J Gen Intern Med","Bates, Carol K","Jackson, Jeff","Asch, Steven","32323135"],"journal":"J Gen Intern Med","authors":["Bates, Carol K","Jackson, Jeff","Asch, Steven"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32323135","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s11606-020-05852-9","weight":0,"_version_":1666138493800153088,"score":59.445827},{"pmid":32343152,"title":"ABO blood group predisposes to COVID-19 severity and cardiovascular diseases.","text":["ABO blood group predisposes to COVID-19 severity and cardiovascular diseases.","Eur J Prev Cardiol","Dai, Xiaofeng","32343152"],"journal":"Eur J Prev Cardiol","authors":["Dai, Xiaofeng"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32343152","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1177/2047487320922370","topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1666138495108775937,"score":43.248608},{"pmid":32379894,"title":"Association between ABO blood groups and risk of SARS-CoV-2 pneumonia.","text":["Association between ABO blood groups and risk of SARS-CoV-2 pneumonia.","In December, 2019, a cluster of acute respiratory illness caused by a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), occurred in Wuhan, China.(1,2) Epidemiological, clinical characteristics, risk factors for mortality of patients infected with SARS-CoV-2, and risk factors in the susceptibility to SARS-CoV-2 included age and chronic disease have been reported.","Br J Haematol","Li, Juyi","Wang, Xiufang","Chen, Jian","Cai, Yi","Deng, Aiping","Yang, Ming","32379894"],"abstract":["In December, 2019, a cluster of acute respiratory illness caused by a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), occurred in Wuhan, China.(1,2) Epidemiological, clinical characteristics, risk factors for mortality of patients infected with SARS-CoV-2, and risk factors in the susceptibility to SARS-CoV-2 included age and chronic disease have been reported."],"journal":"Br J Haematol","authors":["Li, Juyi","Wang, Xiufang","Chen, Jian","Cai, Yi","Deng, Aiping","Yang, Ming"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379894","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/bjh.16797","keywords":["abo blood groups","sars-cov-2","infection","markers","pneumonia"],"locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1666597097271459840,"score":43.248608}]}